Comparative Pharmacology
Head-to-head clinical analysis: LAMICTAL XR versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMICTAL XR versus MYSOLINE.
LAMICTAL XR vs MYSOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces.
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant